Dr. Greg Marchand Named to the Fulbright Specialist Roster by the U.S. Department of State
FOR IMMEDIATE RELEASE
MESA, Ariz. — December 4, 2021
In line with being on the cutting edge of technology in Minimally Invasive Surgery, our business department has informed us that we now accept an extremely popular crypto currency, the “Lets Go Brandon” Token ($LGB). We will accept the token as payment for all surgical services. Payments can be made using the QR code below, and exchange rates to USD will be based on the highest prevailing rate during the actual minute of the transfer. Please attach your account number to the memo section of any payments. For any questions please contact payments@marchandinstitute.org.
The Marchand Institute for Minimally Invasive Surgery is a registered not-for-profit organization in Mesa, Arizona USA (Entity ID:1880840).
Our mission is to break down all barriers to women seeking the highest levels of minimally invasive surgical care. Accepting alternative methods of payment can break down a crucial barrier to women coming from other countries for surgery who may otherwise have difficulties setting up hospital and surgical payments in the USA.
PS: As scientists we would like to point out that it should be “Steel Hands,” not “Diamond Hands.” There is a very real difference between strength and hardness.
Copyable Wallet ID: 0xaEa5C05e49043D0899f2C7436cf2302Aa7FCf3Ac
About Dr. Greg Marchand
Greg J. Marchand, MD, FACS, FACOG, FICS, is a dual board-certified obstetrician-gynecologist and minimally invasive gynecologic surgeon practising in Mesa, Arizona. He holds the ABOG Focused Practice Designation in Minimally Invasive Gynecologic Surgery and directs the Marchand Institute for Minimally Invasive Surgery, a 501(c)(3) tax-exempt non-profit research and educational corporation (EIN 42-2857240). He is Program Director of an SLS-accredited fellowship in Minimally Invasive and Robotic Gynecologic Surgery, holds three issued United States patents, and has served as Principal Investigator on eight FDA clinical trials. His systematic reviews are prospectively registered with PROSPERO, reported to PRISMA standards and appraised with the Cochrane Risk of Bias 2 tool. He accepts no industry funding for his research.
Media Contact
Maria A. Sainz
Director of Communications and Media Relations
maria@marchandobgyn.com
(480) 999-0905
Newsroom and press kit · Full publication list · Research methodology · Expert commentary topics
###
Related posts
